Using memantine to protect memory and cognition during craniospinal irradiation
Memantine to Preserve Memory and Neurocognition Following Craniospinal Irradiation- A Randomised Controlled Trial (MEMENTO)
This study is testing if the drug memantine can help protect memory and thinking skills in patients getting radiation treatment for brain tumors.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 101 (estimated) |
| Ages | 5 Years to 39 Years |
| Sex | All |
| Sponsor | Tata Memorial Centre Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Mumbai, Maharashtra) |
| Trial ID | NCT06275035 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of memantine in preserving memory and neurocognitive function in patients undergoing craniospinal irradiation (CSI) for conditions like medulloblastoma. Participants will be randomly assigned to receive either memantine alongside standard treatment or standard treatment alone. The study aims to assess neurocognitive outcomes through tests conducted before and after radiation therapy. By investigating memantine's potential benefits, the trial seeks to address the cognitive decline often experienced by survivors of CNS tumors post-treatment.
Who should consider this trial
Good fit: Ideal candidates are children and young adults aged 5 to 39 years who are scheduled for craniospinal irradiation.
Not a fit: Patients who have previously received memantine or are undergoing re-irradiation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help prevent memory decline in young patients undergoing craniospinal irradiation.
How similar studies have performed: Previous studies have shown that memantine can effectively prevent memory decline in patients receiving radiation therapy, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age at irradiation: 5 to 39 years * Planned for CSI (with or without boost dose) with or without systemic chemotherapy * Informed consent or assent taken * Karnofsky Performance Status / Lansky Performance Status ≥ 60 Exclusion Criteria: * Re-irradiation * Prior exposure to memantine * Inability to undergo Wechsler test
Where this trial is running
Mumbai, Maharashtra
- Tata Memorial Hospital — Mumbai, Maharashtra, India (Recruiting)
Study contacts
- Study coordinator: Tejpal Gupta, MD
- Email: drtejpalgupta@gmail.com
- Phone: 02224177000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.